An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer

Author： Nuijten Mark J.C.   Aultman Rick   Carpeño Javier de Castro   Vergnenègre Alain   Chouaid Christos   Walzer Stefan   Siebert Uwe  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.27, Iss.11, 2011-11, pp. : 2193-2201

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Erlotinib versus Pemetrexed for Pretreated Non-Squamous Non-Small Cell Lung Cancer Patients in Clinical Practice

By  

Oncology, Vol. 84, Iss. 5, 2013-02 ,pp. : 255-264

Karger

Access to resources Recommend Favorite

The PARAMOUNT Trial: A Phase III Randomized Study of Maintenance Pemetrexed Versus Placebo Immediately Following Induction First-line Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer

By  

Reviews on Recent Clinical Trials, Vol. 8, Iss. 1, 2013-01 ,pp. : 23-28

Bentham Science Publishers

Access to resources Recommend Favorite

Smoking History as a Predictor of Pemetrexed Monotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer

By  

Oncology, Vol. 91, Iss. 1, 2016-05 ,pp. : 41-47

Karger

Access to resources Recommend Favorite

Bevacizumab in the Treatment of Advanced, Non-Squamous Non-Small Cell Lung Cancer: An Evidence-Based Approach

By  

Oncology, Vol. 80, Iss. 5-6, 2011-07 ,pp. : 350-358

Karger

Access to resources Recommend Favorite

A Phase II Randomized Study of Cisplatin-Pemetrexed plus either Enzastaurin or Placebo in Chemonaive Patients with Advanced Non-Small Cell Lung Cancer

By  

Oncology, Vol. 82, Iss. 1, 2012-01 ,pp. : 25-29

Karger

Access to resources Recommend Favorite